Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

por Wang, Yingcheng, Rui, Mingjun, Guan, Xin, Cao, Yingdan, Chen, Pingyu
Publicado 2021

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China

por Meng, Rui, Cao, Yingdan, Zhou, Ting, Hu, Hongfei, Qiu, Yijin
Publicado 2022

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

por Zhou, Ting, Wang, Xintian, Cao, Yingdan, Yang, Lan, Wang, Zijing, Ma, Aixia, Li, Hongchao
Publicado 2022